Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsed or refractory advanced leukemias or MDS~* ECOG 0-2~* Adequate renal function~* Adequate liver function~* ≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery~* ≥ 4 weeks from other investigational anticancer therapy~* Agree to practice effective contraception~Exclusion Criteria:~* Known CNS involvement by leukemia~* Currently receiving radiotherapy, biological therapy, or any other investigational agents~* Uncontrolled intercurrent illness~* Pregnant or lactating~* Known to be HIV-positive~* Known active hepatitis B and/ or hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CYC140 single agent (Type: EXPERIMENTAL): CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).